Post-Market Surveillance and PSUR Requirements in Singapore

1. Key takeaways

Singapore requires companies to establish and maintain a Post-Market Surveillance (PMS) system covering complaint handling, adverse event reporting and FSCA procedures; for Class C and Class D devices, a Periodic Safety Update Report (PSUR) is typically required, commonly on a two-yearly cycle. The post-market surveillance plan itself is also part of the registration dossier (GN-17 R5 / GN-18 R5, ASEAN CSDT), which means the system must be documented and operational before submission, not after approval.

• HSA expects dealers to encourage feedback from all users — healthcare professionals, patients and consumers — as the basis of an effective PMS system.
• The PSUR cycle commonly cited for Class C and D is every 2 years, as an industry compilation; the specific cycle follows HSA requirements and registration conditions.
• Analysis and trending of feedback is an explicit HSA expectation, not an optional extra.
• PSUR output feeds back into the clinical evaluation report (CER, GN-20 R2), closing the loop.

2. Legal basis

The obligations and documents referenced by the PMS regime are summarised below. Note that the two-year PSUR cycle is an industry compilation and must be confirmed against HSA requirements and the conditions attached to each registration.

A complete PMS system in Singapore has five working components, summarised below.

3. Expert insights

Five points explain how the PMS requirement behaves in real projects.

Insight 1: PMS is a document submitted at registration, not something added after market entry. The HSA dossier framework (GN-17 R5 / GN-18 R5) lists the post-market surveillance plan as part of the submission, covering complaint handling, adverse event reporting and FSCA procedures. This means that at the moment you file the registration application, your PMS system should already be documented and able to run. Writing it after approval is a sequencing error that shows up in review and undermines the credibility of the entire dossier.

Insight 2: analysis and trending matter more than collection. The official HSA wording stresses that the analysis and trending of feedback could lead to invaluable insights and improve medical device safety. A system that collects complaints but performs no trend analysis is incomplete in an audit view. When we design PMS for clients, the deliverables of trend analysis are set as a hard, scheduled output, not an aspiration.

Insight 3: the PSUR and the clinical evaluation form a closed loop. Post-market data summarised in the PSUR feeds back to update the conclusions of the clinical evaluation report (CER, GN-20 R2). Treat the two as controlled documents with linked updates, not as separate archives. When one moves, the other is reviewed; otherwise the clinical evaluation quietly goes stale while the evidence base moves underneath it.

Insight 4: the PSUR cycle must follow the registration conditions. The common industry compilation is every two years for Class C and D, but the specific cycle follows HSA requirements and the conditions at the time of the product’s registration. The condition clauses on the approval documents are the highest-authority source; where they differ from the general practice, they prevail. This practical estimate should therefore be treated as a default to be confirmed, not a fixed rule — some products may carry a different periodic reporting obligation written directly into their approval conditions.

Insight 5: in multi-entity structures, PMS data must be capable of consolidation. Complaints and events collected separately by the registrant, the importer and the wholesaler need a mechanism for consolidation. When data is scattered across entities, trend analysis becomes impossible — signals that would be visible in a single dataset never emerge. Our holder services provide a unified case ledger so that every entity’s input lands in one place and the analysis stays complete.

4. Practical recommendations

We recommend the following measures when building or reviewing a PMS system for Singapore.

1. Prepare the PMS plan together with the registration: do not leave it for after market entry.
2. Make trend analysis a hard output: produce reports on a fixed schedule.
3. Link PSUR and CER updates as controlled documents.
4. Fix the PSUR cycle from the condition clauses on the approval documents.
5. Consolidate multi-entity data: maintain a single case ledger.

Regulatory information verified as of: 26 October 2026

Source level: Tier 2 (official HSA post-market surveillance pages; GN-17 R5; GN-18 R5; GN-20 R2; GN-06 R3), Tier 3 (industry compilation of the two-year PSUR cycle, subject to HSA requirements and registration conditions)

5. Verification checklist

• □ The PMS plan was prepared together with the registration dossier
• □ The complaint handling process is documented and operational
• □ The three-tier AE reporting timelines process is established
• □ FSCA procedures are established
• □ Trend analysis is a regular, hard output
• □ The PSUR cycle has been confirmed against registration conditions (typically two years for Class C/D)
• □ A mechanism for consolidating multi-entity data is established
• □ A linked-update mechanism between PSUR and CER is established

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com